Mundipharma submits MAA for opioid overdose reversal treatment

2 November 2016

UK-based Mundipharma International has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the opioid overdose reversal treatment Nyxoid (intranasal naloxone spray).

Mundipharma’s new formulation of a drug which has been in routine practice to reverse the effects of opioid overdose for more than 40 years, is designed to support take-home naloxone programs and provide those who are first on the scene in overdose situations with an easy to use, needle-free option.

Rachel Gooch, head of addiction therapy at Mundipharma International, said: “We know that in emergency circumstances, rapid administration of a reversal agent is critical to preserving life.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK